Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

AprilBio Co.,Ltd.

에이프릴바이오397030KOSDAQSector: Pharma & Biotech
₩17,1204.99%Market cap ₩471.8BAs of Sep 2, 2026 close · updated once daily
Market cap
₩471.8B
#177 in KOSDAQ
Loss
PER not computable
5.16x
Sector median 1.61x
0.0%
Sector median 0.0%
C
Grade C48.4 ptsBottom 45% of 2,523 graded stocksMethodology v2.0
Financial strength
64.7/100
Growth momentum
42.8/100
Price attractiveness
35.3/100
Shareholder Return
37.5/100

As of Sep 2, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCCurrentDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band C with a total score of 48.4 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩17,120High ₩73,300
Latest close
Price change by period
1W
10.70%
1M
22.70%
3M
70.10%
1Y
30.50%

As of the Sep 2, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

64.7/100
How much debt does it carry relative to equity?
0.8%
Sector median 51.6%
Sector lowhighTop 0.2% in sector
Can it cover what's due within a year?
17490.4%
Sector median 191.7%
Sector lowhighTop 0.2% in sector
How much of revenue becomes profit?
-334.4%
Sector median -2.4%
Sector lowhighBottom 15% in sector
How much did it earn on its own capital?
-10.1%
Sector median -4.5%
Sector lowhighBottom 44.3% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

42.8/100
How much did revenue grow in a year?
-92.1%
Sector median 6.4%
Sector lowhighBottom 1.1% in sector
Has it grown steadily over three years?
121.5%
Sector median 4.9%
Sector lowhighTop 4.1% in sector
Did core profits grow in a year?
-143.1%
Sector median 3.6%
Sector lowhighBottom 7.8% in sector
Are core profits higher than three years ago?
36.7%
Sector median 3.5%
Sector lowhighTop 33.6% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

35.3/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 46.4% in sector
Is the price expensive relative to book value?
5.16x
Sector median 1.61x
Sector lowhighBottom 24.1% in sector

Valuation uses the Sep 2, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 3 met · 5 not met · 1 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩9.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩3.3B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
25.1% → -9.8%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩3.3B vs -₩9.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
8.6% → 0.8%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
1139.2% → 17490.4%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
61.3% → -334.4%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.35x → 0.02x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026C

Methodology version change (v2.0 applied)

Jul 15, 2026CVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 4,095,456 new shares, equal to 17.5% of shares outstanding before the increase (filed 2026-07-23). View filing ↗

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 13, 2026Source ↗
Paid-in capital increaseJul 23, 2026Source ↗
Paid-in capital increaseJul 23, 2026Source ↗
Paid-in capital increaseJun 25, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →